Curapod: Revolutionizing Chronic Pain Management in India

Curapod by Litemed is a non-invasive wearable device offering a groundbreaking solution for chronic musculoskeletal pain, changing how pain is treated in India.

Auto-published by Growwh – a smarter way to scale content and marketing. Want to know more? Chat with us.

India’s healthcare system has significantly improved its management of acute diseases, yet chronic conditions, particularly musculoskeletal pain, remain largely underserved. Statistics reveal that nearly 19.3% of the Indian population suffers from chronic musculoskeletal pain. Unfortunately, most patients depend on long-term painkillers, steroid injections, or costly physiotherapy sessions, approaches that come with numerous risks such as side effects, dependency, and high recurring expenses. To address this critical gap, Curapod, a groundbreaking non-invasive wearable device, is making its mark in the field of pain management.

The Innovative Approach of Curapod

Curapod, developed by Litemed, utilizes photobiomodulation therapy to offer targeted pain relief without systemic side effects. This technology employs specific wavelengths of light to promote cellular repair and reduce inflammation, empowering patients to receive hospital-grade interventions from the comfort of their homes.

A Personal Journey to Innovation

The inspiration behind Curapod comes from Sriram (Sri) Velliyur, an electrical engineer with an impressive background in healthcare. His experience at NYU Langone Medical Center exposed him to the limitations of chronic pain management, where he observed that patients were often treated with the same outdated methods—pills and procedures without exploring the best options for individual cases. This led him to partner with Dr. Surya Maguluri, a pharmacist who shared a complementary vision of creating effective, non-invasive therapeutics.

Ready to take your brand to the next level?
At Growwh, we help startups and emerging brands grow faster with powerful content, creator collaborations, and tech solutions.
Explore what we do →

Both Sriram and Surya felt a compelling need to innovate after witnessing friends and family become dependent on medication, prompting them to design Curapod. “We didn’t want to build another wellness gadget. We aimed to create a therapeutic device that could stand up to clinical scrutiny,” Velliyur emphasized.

What Sets Curapod Apart?

Curapod was engineered with significant advancements, such as increasing the penetration depth of therapeutic light from 5mm to 60mm—an impressive twelve-fold improvement—allowing it to effectively treat deeper tissues, joints, and tendons that traditional devices couldn’t reach.

Scientific Validation of Pain Relief

Curapod isn’t just another wearable; it has undergone extensive clinical testing, which included double-blind, randomized, placebo-controlled multicenter trials. These studies indicated a remarkable 50–60% pain relief in just a single 30-minute session for ailments like arthritis, sciatica, frozen shoulder, and tendonitis. With over 100 community treatment camps and more than 3,000 treated patients—some even being athletes from the Sports Authority of India—the data has started to speak volumes, helping physicians regain trust in new technologies.

As a medically certified Class B device in India, Curapod is quickly making its mark in the healthcare sector.

Accessing Relief Made Easy

The device is designed for simplicity of use—applying Curapod to the affected area for 30 minutes, twice a day, over a 7-14 day period, depending on the severity of the condition. Patients with chronic issues such as arthritis or lower back pain find that Curapod serves as a reusable, non-pharmaceutical alternative that eliminates the need for frequent doctor visits or medication refills. With a cost-effective price point around Rs 9,000, and typical discounts bringing it to Rs 7,650, it stands as a worthwhile investment compared to ongoing physiotherapy expenses.

A New Growth Trajectory

Since its soft launch in October 2024, Curapod has experienced a month-on-month revenue growth of 20%. With a goal to reach a revenue run rate of Rs 2 crore by Q4 2025, the startup continues to amplify its presence through direct-to-consumer sales and targeted educational events. They have chosen to abstain from online marketplaces initially to maintain control over brand messaging and customer education.

Strategic Backing and Future Directions

Litemed is backed by angel and institutional investors who enhance its growth with unique insights into manufacturing and distribution pathways. “We’ve raised capital to build a robust, global-grade business,” Velliyur asserted, planting seeds for both domestic and international operations. They are also exploring FDA registration to penetrate U.S. and European markets by February 2026.

Curapod aims to expand its range of wearable devices to tackle not just musculoskeletal pain but also other chronic health issues, such as menstrual pain relief, diabetic neuropathy, migraines, and erectile dysfunction, all grounded in the principles of photobiomodulation and microcirculation enhancement. “Our core belief is that non-invasive care should be as accessible as a pill but without the side effects,” concludes Velliyur.

Conclusion

The launch of Curapod marks a pivotal advance in chronic pain management in India, promising patients a path to real healing rather than mere symptom management. With a foundation built on scientific research and a commitment to safety and efficacy, Curapod is pushing the boundaries of pain relief—transforming the way chronic conditions are managed, one patient at a time.

Source

This article was auto-generated as part of a smart content campaign. Curious how we do it? Chat with us to learn more about our content automation systems.